Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-003 in advanced liver disease (renal function, PK/PD, safety)
2016-002226-36Phase 2Terminated
- Sponsor
- Noorik Biopharmaceuticals AG
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Cirrhosis comparing N-003 arm with Placebo arm (2 arms). Primary endpoint: Change in 24-hour urine volume. Started Nov 2016; status: terminated.
02
Drugs
ambrisentan
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on 2016-002226-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002226-36.